Our Science

Amgen is innovating new ways to get medicines to patients faster. To achieve that, our R&D strategy in clinical trials is focused on leveraging innovative clinical trials design, real world data and digital technologies to accelerate drug development. We are continuously working to achieve equitable access to clinical trials by improving the diversity of participants in a study and ensuring they are more characteristic of a broader patient population.

The sophistication of drug discovery has evolved. Generative Biology and the convergence of machine learning, AI technology and biology reimagines the protein drug discovery process.

Amgen is exploring this new wave of innovation to predict protein structures and reduce discovery timelines with the goal of increasing success rates. Leveraging biology insights, AI and machine learning we are moving from the idea of a protein to a medicine.

At Amgen we believe greater understanding can be found by delving deeper into our DNA. The huge growth of biological data and computational technologies are allowing scientists to perform a wide range of analysis in a much more rapid and cost-effective way than previously possible, even just 20 years prior.

Data science is also changing the way researchers can understand, diagnose, and track diseases for the next generation of first-in-class therapeutics. deCODE, our Icelandic subsidiary, is leading the way in collection and analysis of genomics and to find meaningful insights by applying a multi-omics approach. The use of omics in drug development allows us to deliver transformative therapies.

Conventional medicines are produced to target a protein and attach that protein to alter its activity. Today, many diseases have proteins too big or too complex that are hard to tackle with conventional drugs. This is evolving toward a new approach in drug design called multi specifics. Multi Specifics use an induced proximity process to bring together a disease target and an effector.

It acts on that target, or it uses built in zip codes that deliver the drug to its site of action. Multispecifics are shaping the future of medicine in the biopharmaceutical industry to fight against diseases considered untreatable. They’re using the body’s natural biological mechanisms to reach targets which were considered out of reach previously.